# EDGAR Filing Document

**Accession Number:** 0001628171
**File Stem:** 0001193125-25-151254
**Filing Date:** 2025-6
**Character Count:** 6635
**Document Hash:** 42d7d311ebb01dbbf40a0e1eadbffa22
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-151254.hdr.sgml**: 20250627

**ACCESSION NUMBER**: 0001193125-25-151254

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250626

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250627

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Revolution Medicines, Inc.
- **CENTRAL INDEX KEY:** 0001628171
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472029180
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39219
- **FILM NUMBER:** 251086283

**BUSINESS ADDRESS:**
- **STREET 1:** 700 SAGINAW DR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 415-766-3638

**MAIL ADDRESS:**
- **STREET 1:** 700 SAGINAW DR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 OR 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 26, 2025

## REVOLUTION MEDICINES, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39219** | **47-2029180** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **700 Saginaw Drive**<br> **Redwood City, California** | **94063** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (650) 481-6801
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.0001 par value per share | RVMD | The Nasdaq Stock Market LLC |
| Warrants to purchase 0.1112 shares of common stock expiring 2026 | RVMDW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.**  |

---

On June 26, 2025, Revolution Medicines, Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on three proposals, each of which is described in more detail in the Company's definitive proxy statement (the "Proxy Statement") on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on April 29, 2025. Only stockholders of record as of the close of business on April 28, 2025, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 186,261,742 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), excluding any treasury shares, were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is described below.

*Proposal 1*. The Company's stockholders elected four Class II directors to hold office until the 2028 annual meeting of stockholders or until their respective successors are elected and qualified. The results of the vote were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
|  Frank K. Clyburn, Jr. | 147380169 | 512898 | 10241664 |
|  Sandra J. Horning, M.D. | 126395644 | 21497423 | 10241664 |
|  Sushil Patel, Ph.D. | 126396068 | 21496999 | 10241664 |
|  Thilo Schroeder, Ph.D. | 119696091 | 28196976 | 10241664 |

---

*Proposal 2*. The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025. The results of the vote were as follows:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 157875830 | 214963 | 43938 |

---

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

*Proposal 3*. The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. The results of the vote were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 145265825 | 2597920 | 29322 | 10241664 |

---

No other items were presented for stockholder approval at the Annual Meeting.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **REVOLUTION MEDICINES, INC.** | **REVOLUTION MEDICINES, INC.** |
| Date: June 27, 2025 | By: | /s/ Mark A. Goldsmith |
|  |  | Mark A. Goldsmith, M.D., Ph.D.<br> President and Chief Executive Officer |

---